Publications by authors named "Kumiko Sugio"
Article Synopsis
- The study investigates the R-CHADS-VASc score's ability to predict cardiovascular events in atrial fibrillation (AF) patients post bioprosthetic valve replacement, using data from the BPV-AF registry with 766 participants.
- Patients were classified into low, moderate, and high risk based on their R-CHADS-VASc scores, with results indicating that those with higher scores experienced significantly more cardiovascular events during the follow-up period.
- The findings suggest that the R-CHADS-VASc score is an effective tool for assessing cardiovascular risk in AF patients who have undergone BPV replacement, with higher scores correlating to worse outcomes.
Article Synopsis
- Current guidelines suggest using either DOACs or warfarin for patients with atrial fibrillation who have a bioprosthetic valve, but research on elderly patients (≥80 years) in this context is limited.
- A study analyzed data from 752 patients, revealing that those aged ≥80 had a significantly higher risk of adverse outcomes than younger patients, with a hazard ratio of 2.04.
- The findings indicate that both DOACs and warfarin have comparable efficacy and safety in managing elderly patients with bioprosthetic valves and atrial fibrillation.
Background: Japanese patients undergoing transcatheter aortic valve replacement (TAVR) are often female and have a small body size, potentially impacting bleeding risk with antithrombotic therapy. Outcomes of direct oral anticoagulant use in these patients with atrial fibrillation (AF) need to be clarified.
Methods and results: This prespecified analysis included Japanese patients from ENVISAGE-TAVI AF, a prospective, randomized, open-label, adjudicator-masked trial that compared treatment with edoxaban and vitamin K antagonists (VKAs) in patients with AF after TAVR.
Background: Current guidelines equally recommend direct oral anticoagulants (DOACs) and warfarin for atrial fibrillation (AF) patients with a bioprosthetic valve (BPV); however, there are limited data comparing DOACs and warfarin in AF patients with an aortic BPV.
Methods and results: This post-hoc subgroup analysis of a multicenter, prospective, observational registry (BPV-AF Registry) aimed to compare DOACs and warfarin in AF patients with an aortic BPV. The primary outcome was a composite of stroke, systemic embolism, major bleeding, heart failure requiring hospitalization, all-cause death, or BPV reoperation.
Background: Although bioprosthetic valve (BPV) replacements are becoming more common within our aging society, there are limited prospective data on the appropriate antithrombotic therapy for East Asian patients with atrial fibrillation (AF) and BPV replacement. Antithrombotic therapy and thrombotic and hemorrhagic event rates in Japanese patients with AF and BPV replacement are investigated.
Methods and results: This multicenter, prospective, observational study enrolled patients with BPV replacement and AF.
Purpose: To date, clinical data on real-world treatment practices in Japanese patients with atrial fibrillation (AF) after bioprosthetic valve (BPV) replacement are needed. We conducted a large-scale, prospective, multicenter study to understand the actual usage of antithrombotic therapy and the incidence of thromboembolic and bleeding events in these patients, and to eliminate the clinical data gap between Japan and Western countries.
Methods: This was an observational study, in patients who had undergone BPV replacement and had a confirmed diagnosis of AF, with no mandated interventions.
Background: The incidence of cardiovascular diseases, including valvular heart disease and atrial fibrillation (AF), is rising as the elderly population increases. For patients with AF and bioprosthetic valves, current treatment guidelines for antithrombotic therapy vary by country, likely due to a lack of robust study data.
Methods: We conducted a multicenter, retrospective, observational analysis of 214 Japanese AF patients after bioprosthetic valve replacement in real-world clinical practice.
Purpose: Oncolytic adenoviruses (Ad) have been actively pursued as potential agents for cancer treatment. Among the various types of oncolytic Ads, the telomerase-specific replication-competent Ad (TRAD), which possesses an E1 gene expression cassette driven by the human telomerase reverse transcriptase promoter, has shown promising results in human clinical trials; however, the E1 gene is also slightly expressed in normal cells, leading to replication of TRAD and cellular toxicity in normal cells.
Experimental Design: To overcome this problem, we utilized a microRNA (miRNA)-regulated gene expression system.
Fiber-substituted Ad serotype 5 vectors containing the fiber protein from Ad serotype 35 (Ad5F35) exhibit properties that render them suitable as a platform for targeted Ad vectors. Ad5F35 vectors do not show apparent tropism in certain organs, including the liver, and they elicit less innate immunity than other vectors after intravenous administration. In order to develop a targeted Ad vector, we previously developed fiber-mutant Ad5F35 vectors containing the integrin binding Arg-Gly-Asn (RGD) motif in the FG or HI loop of the Ad35 fiber knob.
View Article and Find Full Text PDF